Trump Plans To Sign Executive Order On The Psychedelic Ibogaine As Soon As This Week, Report Says
When It Comes To Marijuana And Hemp, If You Believe In One Plant You Need To Believe In One Rule (Op-Ed)
Missouri Hemp Businesses Ask Governor To Veto Bill That Would ‘Eliminate’ The Industry
Marijuana Activist Group Asks People To Share Their Arrest Stories To Show The ‘True Impact’ Of Criminalization
Virginia Governor Says Marijuana Bill Amendments Came After Speaking To Colleagues In Other States That Have Legalized
Vaporizing Marijuana Reduces Harmful Inhaled Byproducts By 99% Compared To Joint Smoking, New Study Shows
Federally Funded Study Reveals Marijuana Breathalyzer Breakthrough With 3-D Printed Roadside Tool Able To Detect THC
Alcohol And Tobacco Are More Damaging To Users And Society Than Marijuana Is, Government-Funded Study Concludes
High Marijuana Taxes Don’t Effectively Deter Use, Study Shows, Contrary To NYT Editorial Board’s Claim
Legalizing Marijuana For Recreational Or Medical Use Leads To Reductions In Different Types Of Crime, Study Finds
WNBA Offers To End Marijuana Testing For Women’s Basketball Players As Part Of Reported Deal With Union
DEA Promotes Anti-Marijuana PSA Contest Inviting Students To Warn Peers About THC Dangers On 4/20
Largest Entertainment Arena In US Partners With Cannabis Businesses To Sell THC Drinks At Concerts And Live Events
Woody Harrelson Got Kicked Out Of Two Bars For Smoking Marijuana With Matthew McConaughey’s Mom
State Marijuana Regulators Share Tips On How To Stay Safe And Legal Around The Holidays
Target Expands Involvement In Hemp THC Drinks Market With 72 New Licenses In Minnesota
Marijuana Sales Are Rising And Alcohol Is On The Decline As Consumer Preferences Evolve, Government Data In Canada Shows
Feds Deny Snoop Dogg Request To Trademark ‘Smoke Weed Everyday’ Because Marijuana Is Illegal And Song Lyric Is Too Popular
Marijuana Kiosks For Seniors Are Coming To Independent Living Communities Across Arizona
Montana Retailers Have Sold More Than $1 Billion Worth Of Recreational Marijuana Since Legalization Took Effect
IRS addresses cannabis industry worker tips (Newsletter: April 16, 2026)
Virginia lawmakers push back on governor’s cannabis amendments (Newsletter: April 15, 2026)
Virginia governor wants cannabis bill changes (Newsletter: April 14, 2026)
Texas hemp product ban paused by judge (Newsletter: April 13, 2026)
Trump advisor says someone is “holding up” cannabis rescheduling (Newsletter: April 10, 2026)
Published
on
By
President Donald Trump is reportedly planning to issue an executive order as soon as this week signaling the administration’s willingness to explore the therapeutic benefits and safety of the psychedelic substance ibogaine.
CBS News reported on Thursday that while the administration doesn’t plan to reschedule the psychedelic out of Schedule I of the Controlled Substances Act (CSA) at this time, the move is “meant to open the door to federal funding for further research on its effectiveness with PTSD and traumatic brain injuries, especially among veterans.”
The outlet said that while officials are still in the process of drafting the executive order’s provisions, the aim is to help determine whether ibogaine is what one source described as “snake oil” or is instead a legitimate treatment.
Citing two sources, CBS reported that the president’s move could come within days.
Early research and experience indicates that ibogaine can help people suffering with post-traumatic stress disorder, traumatic brain injuries and drug addiction.
Lawmakers in a number of states have passed legislation to support clinical trials with the aim of developing ibogaine into a legal medication with approval from the Food and Drug Administration (FDA).
Texas officials, for example, recently announced that the state will move ahead with launching its own research program on the psychedelic after the they couldn’t find a company to lead a consortium on the issue under a bill enacted last year.
The reportedly planned federal move on ibogaine comes nearly four months after Trump issued an executive order directing the Department of Justice to completed the process of moving marijuana from Schedule I of the CSA to Schedule III “in the most expeditious manner”—though that still hasn’t happened.
Meanwhile, Health and Human Services (HHS) Secretary Robert F. Kennedy, Jr. said recently that the Trump administration is “very anxious” to create a pathway for access to psychedelics therapy and that top officials across federal agencies want to “get it out to the public as quickly as possible.”
In an interview on the Joe Rogan Experience in February, Kennedy said he’s confident “we’re going to get it done,” with plans to develop and finalize rules that would enable patients with conditions such as post-traumatic stress disorder (PTSD) and depression to access psychedelic substances like psilocybin and MDMA in a “very controlled setting.”
“Everybody in my agency…is very anxious to get a rule out there that will allow these kind of studies and will allow access under therapeutic settings, particularly [for] the military soldiers who have suffered these injuries to get access to these products,” the HHS secretary said. “We’re working through that process now. We’re all working on it and trying to make it happen.”
“I think that we’re going to get it done,” he said.
Last June, Kennedy said his agency is “absolutely committed” to expanding research on the benefits of psychedelic therapy and, alongside of the head of FDA, is aiming to provide legal access to such substances for military veterans “within 12 months.”
VA Secretary Doug Collins also disclosed in April that he had an “eye-opening” talk with Kennedy about the therapeutic potential of psychedelic medicine. And he said he’s open to the idea of having the government provide vouchers to cover the costs of psychedelic therapy for veterans who receive services outside of VA as Congress considers pathways for access.
Bipartisan congressional lawmakers introduced legislation this session to provide $30 million in funding annually to establish psychedelic-focused “centers for excellence” at U.S. Department of Veterans Affairs (VA) facilities, where veterans could receive novel treatment involving substances like psilocybin, MDMA and ibogaine.
Former U.S. House Speaker Newt Gingrich (R-GA) has said ibogaine represents an “astonishing breakthrough” in the nation’s current “sick care system” that’s left people with serious mental health conditions without access to promising alternative treatment options.
Photo courtesy of Flickr/Scamperdale.
Tom Angell is the editor of Marijuana Moment. A 25-year veteran in the cannabis and drug law reform movement, he covers the policy, politics, science and culture of marijuana, psychedelics and other substances. He previously reported for Forbes, Marijuana.com and MassRoots, and was given the Hunter S. Thompson Media Award by NORML and has been named Journalist of the Year by Americans for Safe Access. As an activist, Tom founded the nonprofit Marijuana Majority and handled media relations, campaigns and lobbying for Law Enforcement Against Prohibition and Students for Sensible Drug Policy.
Add Marijuana Moment as a preferred source on Google.
All the cannabis news you need, all in one place. Copyright © 2017-2026 Marijuana Moment LLC ® and Tom Angell